Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & Administrative
Others
Ratios

ENDRA Life Sciences (NDRA) EBIT (2016 - 2021)

ENDRA Life Sciences (NDRA) has disclosed EBIT for 6 consecutive years, with -$3.1 million as the latest value for Q4 2021.

  • Quarterly EBIT fell 36.25% to -$3.1 million in Q4 2021 from the year-ago period, while the trailing twelve-month figure was -$11.5 million through Dec 2021, changed 0.03% year-over-year, with the annual reading at -$5.8 million for FY2025, 46.72% up from the prior year.
  • EBIT for Q4 2021 was -$3.1 million at ENDRA Life Sciences, down from -$2.7 million in the prior quarter.
  • The five-year high for EBIT was -$360697.0 in Q1 2017, with the low at -$3.3 million in Q3 2020.
  • Average EBIT over 5 years is -$2.4 million, with a median of -$2.6 million recorded in 2019.
  • The sharpest move saw EBIT crashed 686.7% in 2018, then increased 27.99% in 2020.
  • Over 5 years, EBIT stood at -$2.3 million in 2017, then grew by 12.79% to -$2.0 million in 2018, then tumbled by 56.31% to -$3.1 million in 2019, then rose by 27.99% to -$2.3 million in 2020, then plummeted by 36.25% to -$3.1 million in 2021.
  • According to Business Quant data, EBIT over the past three periods came in at -$3.1 million, -$2.7 million, and -$3.2 million for Q4 2021, Q3 2021, and Q2 2021 respectively.